Oktober 04, 2021 + Jessica Di Palo
5 Minuten zu lesen
Investment led by MTIP enables the Spanish healthtech company Mediktor to keep on improving their elaborate technology and expand their international presence.
MTIP is excited to announce MTIP Fund II’s fifth investment in Mediktor, the most accurate Artificial Intelligence medical assistant for triage and pre-diagnosis. The closure of a $13M investment round was led by MTIP. Existing investor Alta Life participated in this investment round as well.
Mediktor has developed a medical assistant that is based on Artificial Intelligence (AI). Its technology identifies patient’s symptoms using natural language recognition, allowing the interpretation of more than one symptom at the same time. In the conversation with the medical assistant, the questions require only simple responses and are supported by further explanations and images to create an optimal user experience. The result is a recommendation related to the urgency level of the provided symptoms and a list of possible diseases the patients could be suffering from, guiding them to the right level of care at the right time. The company’s software was clinically validated with a success rate of up to 91.3% in trials with real patients.
Mediktor operates a B2B model, as the company offers a SaaS white label solution working for insurance companies, hospitals, telemedicine platforms, and pharma companies. With offices in Barcelona and New York, Mediktor plans to expand the use of their AI solution around the USA, Europe, and Latin America.
“This round will allow us to further improve our technology to keep us at forefront of the world, and extend the use to improve access to healthcare worldwide”, explains Co-founder and CEO of Mediktor, Cristian Pascual.
“We are committed to provide a clinically validated tool to our users and customers and believe this is a fundamental pillar to get a solid and reliable tool”, mentions Oscar Garcia-Esquirol, Mediktor’s Chief Medical Officer and Co-Founder. “Early next year we will be the first AI symptom checker in a Hospital Emergency Room in Europe”.
Dr. Marc Dietrich, MD, Investment Director at MTIP, comments: “At MTIP, we have deeply analyzed the symptom assessment vertical and see great potential in Mediktor’s superior solution. It enables faster and more competent symptom checking to significantly increase patient-triage effectiveness for health insurances, telehealth providers, and hospitals.” Dr. Christoph Kausch, Managing Partner at MTIP adds: “Healthcare worker shortage is growing at an enormous rate and COVID-19 significantly increased this issue. Patients suffer from unacceptable waiting times and that is why we believe asynchronous assessments will be established as a standard for less severe illnesses. In our opinion, Mediktor is exceptionally positioned to drive this transition and improve care access for patients.”
Cristian Pascual adds: “Our partnership with MTIP, a growth capital investor focused in scaling solutions in the healthtech sector, is a qualitative leap forward. This strategic partnership will boost our growth and create success for both parties”.
Mediktor’s technology is now available in 15 different languages and can be embedded in all types of interfaces: Web, mobile, as a chatbot or integrated with voice or messaging. The company is established in 26 countries around the world serving more than 10 million users.
Mediktor is the most accurate medical assistant based on Artificial Intelligence (AI) for triage and pre-diagnosis. The company was founded in 2011 by Oscar García-Esquirol, intensive care physician, and Cristian Pascual, industrial engineer. They developed a SAAS white-labeled software ready to be embedded into any interface.
A solution based on scientific knowledge and supported by multiple clinical trials conducted internationally. The medical assistant gives a recommendation on the most suitable care available after evaluating the patient’s symptoms.
Mediktor has managed to close agreements with several international health institutions, including health insurance companies, hospital systems, telemedicine platforms, and pharmaceutical companies
MTIP is a healthtech growth capital investor based in Basel, Switzerland. It invests in digital health and digitally-connected medical device companies, with offerings that provide clear health-related economic benefits. Its entrepreneurial investment team, which has complementary private equity skills and exceptional deal-making capabilities, actively works with portfolio companies to boost growth. MTIP efficiently deploys capital to unlock value and generate attractive returns for our investors. Visit www.mtip.ch to learn more.
MTIP invests in Mediktor
Dieser Text erscheint auf allen Übersichtsseiten (z.B. Story-Karussell)
MTIP invests in Mediktor
MTIP investiert in medizinischen Assistenten
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
MTIP invests in Oviva
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round